Decoy Therapeutics (NASDAQ:DCOY) Short Interest Update

Decoy Therapeutics (NASDAQ:DCOY) was the target of a large growth in short interest in June. As of June 30th, there was short interest totaling 156,313 shares, a growth of 7,850.8% from the June 15th total of 1,966 shares. Based on an average daily trading volume, of 1,217,647 shares, the short-interest ratio is presently 0.1 days. Approximately 29.9% of the shares of the stock are sold short.

Decoy Therapeutics Trading Down 5.6%

DCOY stock traded down $0.35 on Friday, reaching $5.91. The company had a trading volume of 18,981 shares, compared to its average volume of 678,565. The firm’s fifty day moving average price is $6.42. The company has a market capitalization of $3.13 million, a P/E ratio of -0.06 and a beta of 0.59. Decoy Therapeutics has a 1 year low of $4.32 and a 1 year high of $415.80.

Decoy Therapeutics (NASDAQ:DCOY) last released its quarterly earnings results on Friday, May 8th. The company reported ($4.18) earnings per share for the quarter. As a group, equities analysts anticipate that Decoy Therapeutics will post -12.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, June 12th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Decoy Therapeutics has an average rating of “Hold” and a consensus target price of $30.00.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.